AIGEN Sciences
New York, United States· Est.
AI‑powered platform that compresses drug discovery timelines by >70%, delivering lead candidates in ~6 months.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered platform that compresses drug discovery timelines by >70%, delivering lead candidates in ~6 months.
Technology Platform
AIGEN’s platform combines BioBERT‑based literature mining, the Meerkat 7B LLM for chemical design, and a high‑throughput docking/ranking engine to generate and prioritize drug candidates in weeks.
Opportunities
Rapid lead generation can dramatically reduce R&D costs and attract pharma partners seeking to accelerate early‑stage programs.
Risk Factors
Unproven ability to translate AI‑generated hits into viable pre‑clinical candidates and reliance on proprietary LLM performance.
Competitive Landscape
Competes with AI‑driven discovery firms like Insilico Medicine and Exscientia; differentiates via LLM‑centric chemistry design and claimed >70% timeline reduction.